How should I evaluate and manage a 57-year-old woman with peripheral neuropathy of the arms and legs, normal cervical spine radiographs, no diabetes, who is taking tirzepatide (Zepbound) and phentermine for weight loss?

Discontinue phentermine immediately and conduct a comprehensive neuropathy workup to identify the cause, as this patient's peripheral neuropathy is likely unrelated to tirzepatide but requires urgent evaluation to rule out treatable etiologies.

Critical First Step: Stop Phentermine

Phentermine must be discontinued. The FDA label explicitly states that phentermine is contraindicated in patients with agitated states and warns about neurological adverse effects including restlessness, tremor, and other central nervous system effects 1. While phentermine itself is not a classic cause of peripheral neuropathy, sympathomimetic agents can exacerbate autonomic dysfunction and mask underlying neurological conditions.

Tirzepatide Assessment

Tirzepatide (Zepbound) is unlikely to be the primary cause of this patient's neuropathy:

• Recent case reports document peroneal nerve neuropathy ("slimmer's paralysis") with rapid tirzepatide-induced weight loss, but this presents as bilateral foot drop specifically, not generalized arm and leg neuropathy 2
• The timeframe and distribution don't match the typical presentation of compression neuropathies from rapid weight loss
• Tirzepatide can exacerbate autonomic symptoms (particularly orthostatic intolerance and tachycardia) in susceptible patients 3, but peripheral sensorimotor neuropathy is not an established adverse effect

Continue tirzepatide for now while completing the workup, but monitor closely for autonomic symptoms (orthostatic dizziness, tachycardia).

Mandatory Diagnostic Workup

Peripheral neuropathy is a diagnosis of exclusion 4. Even without diabetes, numerous treatable causes must be ruled out:

Essential Laboratory Tests:

• Metabolic screening: HbA1c, fasting glucose (prediabetes causes neuropathy)
• Vitamin B12 and folate levels (B12 deficiency is highly treatable)
• Thyroid function (TSH): hypothyroidism causes neuropathy
• Renal function (creatinine, eGFR): uremic neuropathy
• Serum protein electrophoresis: multiple myeloma, paraproteinemia
• HIV testing: HIV-associated neuropathy
• Lipid panel: dyslipidemia is a key factor in neuropathy development 5

Clinical Examination:

• Small-fiber function: pinprick and temperature sensation
• Large-fiber function: vibration with 128-Hz tuning fork, ankle reflexes
• 10-g monofilament testing for loss of protective sensation 4
• Orthostatic vital signs: assess for autonomic neuropathy (>20 mmHg systolic or >10 mmHg diastolic drop) 6

When to Refer to Neurology:

• Asymmetric presentation
• Rapid progression
• Motor predominance or weakness
• Cranial nerve involvement
• Abnormal findings suggesting demyelinating process
• No clear etiology identified on initial workup 7, 8

Symptomatic Pain Management (If Needed)

If the patient has painful neuropathy symptoms, initiate pharmacologic treatment based on the 2024 ADA guidelines 5:

First-Line Options (choose one):

1. Gabapentinoids:

   • Gabapentin 900-3600 mg/day (start 300 mg at bedtime, titrate)
   • Pregabalin 300-600 mg/day (FDA-approved for neuropathic pain)

2. SNRIs:

   • Duloxetine 60-120 mg/day (FDA-approved, also treats depression)
   • Venlafaxine 150-225 mg/day

3. Tricyclic Antidepressants:

   • Amitriptyline 10-75 mg at bedtime (start low in older patients)
   • Caution: Check ECG if cardiovascular risk factors present; avoid if QTc prolongation 9

4. Sodium channel blockers: Consider if other options fail

All of these medications are purely symptomatic and do not reverse nerve damage 9.

Risk Factor Optimization

Even without diabetes, aggressive cardiovascular risk factor management slows neuropathy progression 5:

• Blood pressure control: Target <130/80 mmHg (hypertension is an independent risk factor)
• Lipid management: Optimize lipid profile (dyslipidemia contributes to neuropathy in type 2 diabetes patterns) 5
• Weight loss continuation: The tirzepatide-induced weight loss itself may be beneficial for metabolic health

Common Pitfalls to Avoid

1. Don't assume this is "just" from weight loss medications - missing a treatable cause (B12 deficiency, hypothyroidism, paraproteinemia) would be a critical error
2. Don't continue phentermine - the sympathomimetic effects and CNS adverse effects warrant discontinuation during neurological evaluation
3. Don't delay workup - some causes of neuropathy are time-sensitive (vasculitis, inflammatory neuropathies)
4. Don't assume normal cervical spine films rule out radiculopathy - if symptoms are asymmetric or dermatomal, consider MRI
5. Don't overlook autonomic symptoms - ask specifically about orthostatic dizziness, syncope, gastroparesis, bladder dysfunction 4

Follow-Up Plan

• Recheck in 2-4 weeks after stopping phentermine to assess if symptoms improve
• If workup is negative and symptoms persist, refer to neurology for consideration of nerve conduction studies/EMG or skin biopsy for small-fiber neuropathy
• If pain management is inadequate within your scope of practice, refer to neurology or pain specialist 5